snail family transcriptional repressor 1Genealiases: SLUGH2 · SNA · SNAH · SNAIL · SNAIL1 · dJ710H13.1
Q-omics provides the consensus-scored SNAI1 profile across patient tissues and cancer cell-line models. SNAI1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SNAI1 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SNAI1 RNA expression shows 17,633 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, COAD, and GBM as cancer lineages where SNAI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNAI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNAI1 survival associations across molecular data types. SNAI1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNAI1 RNA expression–survival associations across cancer types. High SNAI1 expression shows unfavorable associations in KIRP, COAD, BRCA, LUSC, THCA and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SNAI1 RNA expression.
This table summarizes SNAI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNAI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNAI1 shows lower tumor expression in THCA, KICH and KIRP and higher tumor expression in COAD, HNSC and READ. The COAD box plot shows higher SNAI1 RNA expression in tumor versus normal tissue (log2 FC = +2.042, t-test p < 0.001).
This table shows molecular features associated with SNAI1 in patient tissues and cancer cell lines. In patient samples, SNAI1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNAI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and STOMACH.
